儿童与青少年散发性及2型神经纤维瘤病相关脑膜瘤
该回顾性研究分析了1982至2021年间在HIT-ENDO、KRANIOPHARYNGEOM 2000/2007及KRANIOPHARYNGEOM Registry 2019试验/登记中招募的115例儿童脑膜瘤患者,中位诊断年龄10.6岁,男女比例1:1,14%合并2型神经纤维瘤病(NF2)。肿瘤位置以大脑半球(46%)最常见,WHO I级占50%、II级37%、III级6%;WHO I级患者的无事件生存期优于II级患者(p=0.008)。作者结论认为与既往文献的主要差异在于WHO分级分布及其对无事件生存期的影响,并指出需前瞻性研究评估不同治疗方案的影响。
要点
- 儿童脑膜瘤中14%合并NF2,NF2患者多发脑膜瘤占69%,散发性者仅9%。
- 肿瘤位置:大脑半球46%、视神经/眶内17%、脑室10%。
- WHO I级无事件生存期优于II级(p=0.008),中位进展/复发间隔1.9年。
核心结论
- 与既往文献相比,主要差异在于不同WHO分级的分布及其对无事件生存期的影响。
- 需要前瞻性研究评估不同治疗方案的影响。
研究设计与样本
- 回顾性分析1982年至2021年间在HIT-ENDO、KRANIOPHARYNGEOM 2000/2007及KRANIOPHARYNGEOM Registry 2019试验/登记中招募的NF2相关或散发性儿童脑膜瘤患者资料,共115例。
主要发现
- 115例患者中位诊断年龄10.6岁,男女比例1:1,14%患NF2。
- 肿瘤位置:大脑半球46%、视神经/眶内17%、脑室10%。
- NF2患者多发脑膜瘤占69%,散发性脑膜瘤患者中占9%。
- WHO分级:I级50%、II级37%、III级6%。
- 进展或复发的中位间隔为1.9年;8例(7%)死亡,其中3例死于疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pediatric meningioma differs not only in its rare incidence from the adult meningioma, but also in its clinical characteristics. Many treatment approaches of pediatric meningioma are based on the study results of adult meningioma studies. The aim of this study was to explore the clinical and epidemiological characteristics of pediatric meningioma. METHODS: Data on pediatric patients diagnosed between 1982 and 2021 with NF2-associated or sporadic meningioma and recruited in the trials/registries HIT-ENDO, KRANIOPHARYNGEOM 2000/2007 and KRANIOPHARYNGEOM Registry 2019 were retrospectively analyzed for clinical characteristics, etiology, histology, therapy, and outcome. RESULTS: One hundred fifteen study participants were diagnosed with sporadic or NF2-associated meningioma at a median age of 10.6 years. There was a 1:1 sex ratio, with 14% of study participants suffering from NF2. 46% of the meningiomas were located hemispherically, 17% at the optic nerve/ intraorbital and 10% ventricularly. Multiple meningiomas were detected in 69% of NF2 patients and in 9% of sporadic meningiomas. 50% of the meningiomas were WHO grade I, 37% WHO grade II and 6% WHO grade III. Progressions or recurrences occurred after a median interval of 1.9 years. Eight patients (7%) died, 3 of them due to disease. The event-free survival was higher for WHO grade I than for WHO grade II meningioma patients (p = 0.008). CONCLUSIONS: The major difference to the preceding literature could be found in the distribution of different WHO grades and their influence on event-free survival. Prospective studies are warranted to assess the impact of different therapeutic regimens. CLINICAL TRIAL REGISTRATION NUMBERS: NCT00258453; NCT01272622; NCT04158284.
引用
- Wagener K, Beckhaus J, Boekhoff S, et al. Sporadic and neurofibromatosis type 2-associated meningioma in children and adolescents. J Neurooncol. 2023. PMID: 37402092. doi:10.1007/s11060-023-04344-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。